| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:Etazolate hydrochloride
CAS:35838-58-5
Purity:solid Package:5MG Remarks:E1896-5MG
|
|
| | ETAZOLATE Basic information |
| Product Name: | ETAZOLATE | | Synonyms: | 1-ethyl-4-[(1-methylethylidene)hydrazino]1h-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester hydrochloride;SQ20009, 1-Ethyl-4-[(1-methylethylidene)hydrazino]1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester hydrochloride;1H-Pyrazolo[3,4-B]pyridine-5-carboxylic acid, 1-ethyl-4-[(1-methylethylidene)hydrazino]-, ethyl ester, monohydrochloride;Ethyl 1-ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo[3,4-B]pyridine-5-carboxylate monohydrochloride;Nsc163611;Etazolate hydrochloride solid | | CAS: | 35838-58-5 | | MF: | C14H18N5O2HCl | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | 35838-58-5.mol |  |
| | ETAZOLATE Chemical Properties |
| Melting point | 193-194 °C | | storage temp. | room temp | | solubility | H2O: >20mg/mL (Solutions should be freshly prepared.) | | form | solid | | color | white | | Water Solubility | H2O: >20mg/mL (Solutions should be freshly prepared.) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 |
| | ETAZOLATE Usage And Synthesis |
| Uses | Antipsychotic. | | Uses | Etazolate Hydrochloride is an acyclic nucleotide phosphodiesterase 4 inhibitor, which also exhibits antidepressant-like activity in acute and chronic mouse and rat model of depression. | | Biological Activity | etazolate hydrochloride is a pde-4 inhibitor and selective gaba-a receptor modulator [3].pde-4 modulates the release of inflammatory mediators through camp-dependent and -independent mechanisms. selective targeting pde-4 is a novel therapeutic approach in the treatment of inflammation-associated respiratory diseases, such as asthma and copd (chronic obstructive pulmonary disease) [1].in rat neuronal cortical cells, etazolate hydrochloride (0.2 μm) induced sappα through the stimulation of the α-secretase pathway, and exerted a neuroprotective effect against aβ which was associated with sappα induction via the gaba-a receptor [2].in 159 alzheimer’s disease patients, etazolate hydrochloride in combination with one achei (acetycholinesterase inhibitor) was shown to be safe and generally well tolerated in the phase iia study over a 3-month treatment period [3]. | | Biochem/physiol Actions | Selective inhibitor of cAMP-specific phosphodiesterase. | | in vivo | Etazolate hydrochloride (SQ 20009; 1, 3, 10 mg/kg; IP) improves recognition memory and reduces locomotor hyperactivity in a persistent manner following traumatic brain injury (TBI) in mice[3].
Etazolate hydrochloride (0.5, 1 mg/kg; p.o.; once a day during 21 days) significantly inhibits the chronic unpredictable mild stress (CUMS)-induced behavioral (decreases sucrose consumption and increases duration of immobility) and biochemical (increases lipid peroxidation and nitrite level; decreases glutathione, superoxide dismutase and catalase activity) changes in Swiss Albino mice (22-25 g)[4].
Etazolate hydrochloride (0.5, 1 mg/kg; i.p.; single dose) antagonizes the Reserpine (HY-N0480; 1 mg/kg; i.p.)-induced hypothermia in male Wistar rats (250-275 g)[5].
| Animal Model: | Male Swiss mice with 28-30 g[3] | | Dosage: | 1, 3, 10 mg/kg | | Administration: | IP | | Result: | Reduced cerebral ?dema when delivered 5 min and 2 h post-TBI.
Improved recognition memory and reduces locomotor hyperactivity in a persistent manner following TBI.
|
| | IC 50 | PDE4: 2 μM (IC50) | | references | [1] dastidar s g, rajagopal d, ray a. therapeutic benefit of pde4 inhibitors in inflammatory diseases.[j]. current opinion in investigational drugs, 2007, 8(5):364-72.
[2] marcade m, bourdin j, loiseau n, et al. etazolate, a neuroprotective drug linking gaba(a) receptor pharmacology to amyloid precursor protein processing.[j]. journal of neurochemistry, 2008, 106(1):392-404.
[3] vellas b; sol o; snyder pj; ousset pj; haddad r; maurin m; lemarié jc; désiré l; pando mp; eht0202/002 study group. eht0202 in alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study.[j]. current alzheimer research, 2011, 8(2):203-12. |
| | ETAZOLATE Preparation Products And Raw materials |
|